HealthRX NAD+ Review: $161 Injection Plan and What Is Included

HealthRX is one of the easier NAD+ offers to evaluate before an intake: its injection page publishes a $161 monthly selection, a 1,000 mg monthly supply, and the larger payments attached to longer plans. That transparency is its strongest feature. It helps you compare a purchase without claiming that a better-described product is a proven treatment for fatigue or brain fog.

We reviewed the public product page, catalog, terms, and refund policy. We did not buy medication, submit medical information, or test delivery and follow-up care. This assessment covers what a prospective patient can verify publicly and what still needs an individual written quote.

What the monthly plan buys

The injection page shows $161 billed monthly and a stated 1,000 mg per month. It lists the provider visit, medication, injection supplies, unlimited follow-ups, and expedited shipping as included. Its comparison identifies the route as subcutaneous injection.¹

A published quantity makes the price more informative than a bare monthly headline. It gives you something specific to discuss with the prescribing practice. It is not an instruction to administer that total at once, and it does not tell us how any individual's doses should be divided. The prescribed concentration and schedule belong on the actual dispensing label.

The catalog separately lists a NAD+ nasal spray from $134 per month.² That is a second route, not a cheaper version of an identical clinical treatment. Someone who dislikes needles can ask about it, but the convenience of a spray should not be mistaken for proof of comparable exposure or results.

Longer plans lower the equivalent, increase the commitment

The injection selector publishes $434 for three months, $821 for six, and $1,546 for twelve alongside rounded monthly equivalents. It offers subscription and one-time purchase controls, and the subscription wording describes automatic renewal.¹ Confirm the selected purchase type and final payment summary rather than assuming every displayed figure applies at once.

A $1,546 payment is a different decision from a $161 payment even when the monthly equivalent looks attractive. Longer terms tie up more cash while you are still learning whether a plan suits your needs. Before prepaying, ask what happens to an unused portion if the clinician stops treatment, your prescription changes, or you decide not to continue.

For an initial comparison, we would use the shortest clearly priced plan first. The RxSpan MD review also separates base prices from multi-month totals. Those totals help illustrate why the lowest monthly equivalent should not automatically win a price ranking. Willow is another comparison to read when considering an injection offer; check the supply details as carefully as the price.

Approval comes after review, not after payment

HealthRX describes itself as a marketplace connecting patients with independent licensed providers and pharmacies. Its terms distinguish the platform from medical decision-making and dispensing.³ This means a successful checkout is not confirmation that a prescription will be issued.

The injection page says medical review follows purchase and that a clinician determines suitability before shipping. It also says an unsuitable request receives a refund for the medication.¹ That language deserves a close reading beside the refund policy, especially when choosing a prepaid term. Ask about any non-medication charges and the exact point at which the order becomes non-refundable.

The general refund policy says prescription sales are final once charged and handed to the carrier. It allows future subscription renewals to be canceled by emailing support, while canceling does not return medication already dispensed.⁴ Keep a written record of a cancellation request and confirm that a renewal has actually stopped. A subscription control and a pharmacy return are separate issues.

The best disclosure is the evidence limitation

HealthRX's injection page explicitly calls the product investigational and says there is not solid human evidence for outcomes such as less fatigue or slower aging. That is more useful to a prospective patient than an assured results timetable.¹ We would still evaluate the cited research independently rather than relying on the provider's summary.

A randomized oral NR trial increased blood NAD+ without improving cognition; a later trial also reported no cognitive benefit versus placebo.⁵⁶ Neither tested the HealthRX injection or spray. The findings therefore do not establish the effectiveness or ineffectiveness of those finished products. They do show why a biochemical explanation is insufficient to promise better thinking.

We also would not carry a safety percentage from an infusion study over to a home subcutaneous product without checking the original route and study population. A useful safety discussion identifies which preparation was studied, what was measured, how long follow-up lasted, and what remains unknown. Our NAD+ evidence review keeps those categories separate.

What remains unclear for a buyer

The public pages reviewed describe licensed compounding and Section 503A preparations, but did not identify which named pharmacy would fill a particular NAD+ order. We would request that assignment, its contact details, the concentration, storage instructions, and beyond-use date before use. An image of a cleanroom cannot answer those questions for an individual prescription.

The FDA explains that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.⁷ That limitation applies even when a provider publishes good commercial information. Transparent billing and adequate medication evidence answer different questions.

It is also worth asking what ongoing follow-up means in practice. Is a reply from a prescriber available when a symptom arises, or does a support team route the message onward? How does the practice decide to stop or change treatment? We did not test these services, so our review does not score response time or patient satisfaction.

Our verdict: HealthRX deserves a shortlist position for its readable injection supply and billing terms. The opportunity to compare before intake is useful, and its evidence caveats are welcome. The main reasons to pause are prepaid commitments, the unconfirmed pharmacy assignment for your order, and a lack of established cognitive benefit. Use the injection comparison to compare route and quantity, and discuss persistent brain fog with a clinician before treating a wellness purchase as the answer.